Effient Review Delayed More By Management Issues Than Clinical Disputes
Executive Summary
Review management issues, more than unresolved clinical debates, are what produced FDA's lengthy and overdue review of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel), FDA review documents indicate